Nicolás Abad lost his father—a Colombian doctor nicknamed “Telepatia” for his uncanny diagnostic skills—to a preventable drug interaction just days before ChatGPT debuted. Now Abad is channelling that loss into Telepatia, an AI-native clinical platform designed for Latin America’s 700 million people and acute clinician shortage. With $33 million in Series A funding led by a16z, Telepatia combines AI-driven documentation, real-time decision support, and a suite of AI “employees” (doctors, nurses, auditors) trained on global guidelines and local protocols. Since its July 2025 launch, Telepatia has rolled out in over 25 hospital systems across Brazil, Colombia, and Mexico, serving 14 million patients. Doctors report protocol adherence rising from 84% to 99%, and they recover an average of 1.7 hours daily, time redirected to patient care. The platform has already intercepted 60,000 medical errors in real time, letting clinicians correct treatment on the spot. Mater Dei CEO José Henrique Dias Salvador says physicians use Telepatia eight hours a day—an adoption rate he’s never seen before. Latin America’s top 100 hospitals employ half the region’s clinicians, so breaking into a handful of major systems can drive rapid, compounding growth. Telepatia is targeting those key logos first, betting on the region’s clean-slate advantage versus the U.S. market’s legacy-software mess. Alongside a16z, backers include Palantir CTO Shyam Sankar, Rappi founder Simón Borrero, and Nubank founder David Vélez. Abad dreams of landing the first Latin American Nobel Prize in Medicine since 1984. He points to recent Nobel wins in Physics and Chemistry powered by AI as proof that the next leap—this time in medicine—will come from the same technology.